MIB-1 assessments in breast cancers

Breast

Volumn 11, Issue 3, 2002, Pages 252-256

  Iqbal, S ^a   Anderson, T J ^a   Marson, L P ^b   Prescott, R J ^c   Dixon, J M ^a   Miller, W R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN POLYMORPHISM; TISSUE SECTION; TUMOR BIOPSY;

EID: 0036311841     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2002.0408     Document Type: Article

References (14)

1. The cell cycle in breast cancer
2. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis
3. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67
4. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse free survival
5. Effect of tamoxifen on Ki-67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
6. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor positive human breast cancer by tamoxifen
7. Effect of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: An immunocytochemical study
8. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
9. Quantitative growth fraction evaluation with MIB-1 and Ki67 antibodies in breast carcinoma
10. Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated by MIB1 antibody
11. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUPT nick end labeling
12. MIB-1 in relation to tumour response and survival in patients with breast cancer treated with primary systemic therapy
13. Regional heterogeneity in breast carcinoma: Thymidine labelling index, steroid hormone receptor, DNA ploidy
14. Intratumour variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis